Ann: Managing Director's Report, page-5

The 1st strike is probably a warning shot to displace Vanda Gould.....The market is not in the least concerned.
Nothing really to dislike about the business....A turnaround story that has a long way to go.
# Cashed up.
# Retired all debt.
# Ultralute sales later this year.
# Sales in Russia in the short term.
# May open up the big US market.
# COPD applications if trials successful will dwarf current use in the relatively small PE diagnostics.....This will propel CYC into the stratosphere.
Not often we see this terrific value...Pity about the liquidity.